Login / Signup

The Use of an Organo-Selenium Peptide to Develop New Antimicrobials That Target a Specific Bacteria.

Phat TranJonathan KopelJoe A FralickTed W Reid
Published in: Antibiotics (Basel, Switzerland) (2021)
This study examines the use of a covalently selenium-bonded peptide and phage that binds to the Yersinia pestis F1 antigen for the targeting and killing of E. coli expressing this surface antigen. Using a Ph.D.-12 phage-display library for affinity selection of the phage which would bind the F1 antigen of Y. pestis, a phage displaying a peptide that binds the F1 antigen with high affinity and specificity was identified. Selenium was then covalently attached to the display phage and the corresponding F1-antigen-binding peptide. Both the phage and peptides with selenium covalently attached retained their binding specificity for the Y. pestis F1 antigen. The phage or peptide not labeled with selenium did not kill the targeted bacteria, while the phage or peptide labeled with selenium did. In addition, the seleno-peptide, expressing the F1 targeting sequence only, killed cells expressing the F1 antigen but not the parent strain that did not express the F1 antigen. Specifically, the seleno-peptide could kill eight logs of bacteria in less than two hours at a 10-µM concentration. These results demonstrate a novel approach for the development of an antibacterial agent that can target a specific bacterial pathogen for destruction through the use of covalently attached selenium and will not affect other bacteria.
Keyphrases
  • pseudomonas aeruginosa
  • escherichia coli
  • computed tomography
  • cancer therapy
  • cystic fibrosis
  • cell proliferation
  • cell death
  • mass spectrometry
  • pet imaging
  • amino acid
  • wild type